Romosozumab in Women With Chronic SCI

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

June 10, 2024

Study Completion Date

June 10, 2024

Conditions

OsteoporosisBone LossOsteopenia, OsteoporosisSpinal Cord InjuriesChronic Spinal Paralysis

Interventions

DRUG

Romosozumab

Year 1 study drug

DRUG

Alendronate

Year 2 study drug

Trial Locations (1)

Northwestern University Feinberg School of Medicine, Chicago